Long-term Psoriasis cured by 30,000 to 60,000 IU of Vitamin D daily (pictures and video) – early 2022


Daily oral vitamin D3 without concomitant therapy in the management of psoriasis: A case series

Clinical Immunology Communications 2 (2022) 17-22 https://doi.org/10.1016Zj.clicom.2022.01.001
Renu Mahtania (See video below), Pradeep M.K. Nairb>*
a Dr. Renu Mahtani's Param Health - Autoimmunity Treatment Centre, Pune, India
b Sant Hirdaram Medical College of Naturopathy & Yogic Sciences, Sant Hirdaram Nagar, Bhopal 462020, India

Before/After images pf Case 3

Image

Abstract

Evidence suggests vitamin D3 resistance with gene polymorphisms related to its metabolism to have a potential role in the patho-prognosis of psoriasis. We report 6 cases of psoriasis treated with daily oral Vitamin D3 (25 hydroxy cholecalciferol) in doses ranging from 30,000 IU to 60,000 IU over a period of 2 to 6 months and then followed by lower daily maintenance dose. The dose of vitamin D3 was adjusted based on the drop in the level of parathyroid hormone as the ionized calcium levels were also periodically monitored to prevent hypercalcemia.

Complete control of psoriasis was observed within a span of 2-6 months, which was measured by Psoriasis Area and Severity Index (PASI) and a symptom Visual analog scale. Our observations suggest that supervised, daily oral higher than usual Vitamin D3 can be given safely as an effective therapeutic modality for treating psoriasis.
 Download the PDF from VitaminDWiki


Daily oral vitamin D3 without concomitant therapy in the management of psoriasis: A case series - Dec 2022

Clinical Immunology Communications Volume 2, December 2022, Pages 17-22 https://doi.org/10.1016/j.clicom.2022.01.001
Renu Mahtani a, Pradeep M.K. Nair b,
a Dr. Renu Mahtani’s Param Health - Autoimmunity Treatment Centre, Pune, India
b Sant Hirdaram Medical College of Naturopathy & Yogic Sciences, Sant Hirdaram Nagar, Bhopal 462020, India
Highlights

  • Vitamin D3 and resistance and subsequent deficiency play an important role in the pathogenesis of psoriasis.
  • A high daily dose of vitamin D3 is a safe therapeutic option in managing psoriasis.
  • Vitamin D3 therapy offers complete remission of psoriasis without any adverse events.
  • The results of this case series warrants robust clinical trials.

Evidence suggests vitamin D3 resistance with gene polymorphisms related to its metabolism to have a potential role in the patho-prognosis of psoriasis. We report 6 cases of psoriasis treated with daily oral Vitamin D3 (25 hydroxy cholecalciferol) in doses ranging from 30,000 IU to 60,000 IU over a period of 2 to 6 months and then followed by lower daily maintenance dose. The dose of vitamin D3 was adjusted based on the drop in the level of parathyroid hormone as the ionized calcium levels were also periodically monitored to prevent hypercalcemia. Complete control of psoriasis was observed within a span of 2–6 months, which was measured by Psoriasis Area and Severity Index (PASI) and a symptom Visual analog scale. Our observations suggest that supervised, daily oral higher than usual Vitamin D3 can be given safely as an effective therapeutic modality for treating psoriasis.
 Download the PDF from VitaminDWiki
Clipped from PDF: "This case series reports 100% adherence to Vitamin D3 therapy, as the patients were motivated by the results"


15 minute video presentation of this study in Germany May 2022 - with 34 slides

YouTube
 24 slides presented
Image

    • 40% of patients got 80-100% improvement

Some of her videos on VitaminDWiki


Psoriasis in VitaminDWiki

Some of the 70 Psoriasis articles

VitaminDWiki would suspect an even faster cure if Topical Vitamin D had been used

The founder of VitaminDWiki has used Topical Vitamin D for over a decade.
Only need a few drops on my knee once every 4 months
Topical appears to provide 100X higher concentration of vitamin D to the skin than oral

Title change made July 2022 caused the visitor count to reset.
There have actually been 3984 visitors to this page since it was originally made



3807 visitors, last modified 22 Nov, 2022,
Printer Friendly Follow this page for updates